Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Interferon activation in bone marrow long-lived plasma cells in systemic lupus erythematosus.
Front Immunol
January 2025
Division of Allergy, Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, United States.
While durable antibody responses from long-lived plasma cell (LLPC) populations are important for protection against pathogens, LLPC may be harmful if they produce antibodies against self-proteins or self-nuclear antigens as occurs in autoimmune diseases such as systemic lupus erythematosus (SLE). Thus, the elimination of autoreactive LLPC may improve the treatment of antibody-driven autoimmune diseases. However, LLPC remain a challenging therapeutic target.
View Article and Find Full Text PDFCase report: Kikuchi-Fujimoto disease presenting with persistent fever and widespread lymphadenopathy in a young adult.
Front Immunol
January 2025
Department of General Practice, The Affiliated Panyu Central Hospital, Guangzhou Medical University, Guangzhou, China.
Kikuchi-Fujimoto disease (KFD) is a rare, self-limiting condition typically characterized by fever and lymphadenopathy. The exact etiology remains unclear but is suspected to be associated with viral infections and autoimmune responses. This report presents the case of a 32-year-old Chinese male who was admitted with recurrent high fever, lymphadenopathy, and hepatosplenomegaly.
View Article and Find Full Text PDFComparative efficacy and safety of different recommended doses of telitacicept in patients with systemic lupus erythematosus in China: a systematic review and meta-analysis.
Front Immunol
January 2025
State Key Laboratory of Quality Research in Chinese Medicine, Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology, Macao, Macao SAR, China.
Background: Telitacicept, a new biological agent, was approved in China for treating systemic lupus erythematosus (SLE) in 2021. Its optimal dosing for treating SLE remains unclear. Therefore, the aim of this meta-analysis is to evaluate the efficacy and safety of various telitacicept doses in SLE treatment.
View Article and Find Full Text PDFClinical Characteristics, Microbiological and Risk Factors of Infections in Patients With Systemic Lupus Erythematosus.
J Community Hosp Intern Med Perspect
January 2025
Department of Nephrology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Objective: To determine risk factors, clinical and microbiological characteristics of infections in a single-center systemic lupus erythematosus (SLE) cohort.
Methods: All hospital patients in The First Affiliated Hospital of Zhengzhou University from 2019 to 2021 who meet ≥4 ACR-97 SLE criteria were identified. Patients with infection and without infection were included with a ratio of 1:2.
Prevalence and Clinical Assessment of Skin Lesions in Systemic Lupus Erythematosus.
Cureus
December 2024
Emergency and Accident, District Headquarter Hospital, Jhelum Valley, Muzaffarabad, PAK.
This retrospective study analyzes the histopathological patterns of skin lesions in 430 patients with systemic lupus erythematosus (SLE), meeting the American College of Rheumatology criteria from 2018-2023. Patient demographics reveal a mean age of 43.56 years, with a near-equal gender distribution (50.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!